Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610104 | 0.80 | KDM4E (1.00) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9328808 | 0.78 | SMN1; SMN2 (1.00) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10177081 | 0.77 | SMN1; SMN2 (0.64) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10177083 | 0.77 | KMT2A (0.65) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8780447 | 0.76 | PRMT5 (0.60) | POLBSMN1; SMN2ALDH1A1LMNAPARP1 | |
| SCHEMBL5010738 | 0.76 | SMN1; SMN2 (1.00) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL28857250 | 0.75 | PRMT5 (0.58) | POLBSMN1; SMN2ALDH1A1LMNAPARP1 | |
| SCHEMBL12955347 | 0.75 | PARP1 (0.89) | PARP1 | |
| SCHEMBL5717747 | 0.74 | LMNA (1.00) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL30151141 | 0.74 | LMNA (1.00) | KDM4EPOLBSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010108187-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KDM4E 1620/4885POLB 2033/4885SMN1; SMN2 4251/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KDM4E 1620/4885POLB 2033/4885SMN1; SMN2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.